Department of Health and Human Services Secretary Alex Azar and Inspector General Daniel Levinson have issued a proposed rule, “Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in
Prescription Drugs & Other Medical Products
Drugs and other medical products greatly impact human health and the health care system. ASPE conducts a variety of research in this area, including work related to medical product development and regulation; medical product markets, pricing and competition; prescription drug benefits and spending on medical products; medical product supply chains; and medical product safety.
Noteworthy
Reports
Displaying 101 - 110 of 177. 10 per page. Page 11.
Advanced SearchMedication-Assisted Treatment for Opioid Use Disorder in the Child Welfare Context: Challenges and Opportunities
This brief describes four key challenges related to the use of medication-assisted treatment (MAT) in child welfare contexts for parents with opioid use disorder. It draws upon results from a mixed methods study examining how substance use affects child welfare systems across the country. Key challenges discussed include:
ASPE Issue Brief
Using Telehealth to Support Opioid Use Disorder Treatment Issue Brief
This Issue Brief was informed by an ASPE-funded study conducted by RTI International that assessed the use of telehealth to identify and manage SUDs in rural areas. The final research brief included an environmental scan and site visits with participants that represented a wide range of telehealth experiences throughout the country.
Comparison of U.S. and International Prices for Top Medicare Part B Drugs by Total Expenditures
The prices charged by drug manufacturers to wholesalers and distributors (commonly referred to as exmanufacturers prices) in the United States are 1.8 times higher than in other countries for the top drugs by total expenditures separately paid under Medicare Part B. U.S. prices were higher for most of the drugs included in the analysis, and U.S.
Cost Drivers in the Development and Validation of Biomarkers Used in Drug Development
Despite the increasing investment and interest in drug development, the amount of time and resources needed to develop a new drug continues to rise. Biomarkers are an important tool with the potential to decrease the time, cost, and failure rate of drug development.
Addressing the Opioids Crisis: Data Sources and Linking Strategies
This report highlights key research questions and identifies opportunities to use existing data sources and implement data-linking strategies that can support the HHS five point strategy to combat the opioid crisis.
ASPE Data Point
Data point: Prescription Pharmaceutical Price Changes since the Release of the President’s Drug Pricing Blueprint
Using manufacturer-reported prescription pharmaceutical prices, we observe that the number of price increases has been reduced considerably since the release of the President’s Drug Pricing Blueprint, compared to the same time period in the year prior.
State and Local Policy Levers for Increasing Treatment and Recovery Capacity to Address the Opioid Epidemic: Final Report
This report summarizes financing and workforce policies that can be used by states to expand treatment access and capacity for opioid use disorder (OUD), focusing especially on medication-assisted treatment (MAT).
ASPE Data Point
Data Point: Savings Available Under Full Generic Substitution of Multiple Source Brand Drugs in Medicare Part D
ASPE analyzed Part D prescription drug event data from 2016 to estimate spending on brand drugs with generic therapeutic equivalents.
Economic Opportunity and the Opioid Crisis: Geographic and Economic Trends
This study examines relationships between indicators of economic opportunity and the prevalence of prescription opioids and substance use in the United States. We have three primary findings: